
|Videos|August 18, 2014
Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer
Author(s)Suzanne A. W. Fuqua, PhD
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.
Advertisement
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.
Fuqua says there is a fairly high frequency of this mutation in metastatic breast cancers. These mutations are estrogen independent, meaning that hormones are not needed to activate the receptor. The clinical assumption is that the mutation would confer resistance to an aromatase inhibitor, Fuqua says. However, there is no direct clinical evidence of this because the majority of patients that have been examined have undergone multiple rounds of hormonal therapy.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Sacituzumab Govitecan Approved in Europe for First-Line PD-L1 Inhibitor–Ineligible TNBC
2
Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC
3
Allogeneic BCMA CAR T-Cell Therapy CT0596 Elicits 100% ORR in R/R Myeloma and Plasma Cell Leukemia
4
NCCN Includes PCR ctDNA-MRD Testing in MIBC Treatment Algorithm
5




















































































